BNF:

Not listed

Status:

Do Not Prescribe (DNP), Red

Decision Date:

November 2016

Comments

RED: NICE TA416 for treating locally advanced or metastatic EGFR T790M mutation positive non-small cell lung cancer. (Decision date  - November 2016)

RED: NICE TA653 for treating EGFR T790M mutation-positive locally advanced or metastatic NSCLC. (Decision date - November 2020)

RED: NICE TA654 for untreated EGFR mutation-positive NSCLC. (Replaces TA621). (Decision date - November 2020)

RED: NICE TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. (Decision date - February 2022)

DO NOT PRESCRIBE (DNP): NICE TA621 - for untreated EGFR mutation-positive non-small-cell lung cancer. (Decision date - February 2020)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again